Endoscopic injection sclerotherapy with ligation versus endoscopic injection sclerotherapy alone in the management of esophageal varices: a prospective randomized trial

Shigemitsu, T.; Yoshida, T.; Harada, T.; Takeo, Y.; Nakamura, H.; Okita, K.

Hepato-Gastroenterology 47(33): 733-737

2000


ISSN/ISBN: 0172-6390
PMID: 10919021
Accession: 010585127

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
Background/Aims: Endoscopic injection sclerotherapy with ligation is a technique by which endoscopic injection sclerotherapy is first carried out for a target esophageal varix using an endoscope equipped with a device for endoscopic variceal ligation, and subsequently, endoscopic variceal ligation is performed for the varix together with the injection site of the sclerosing agent. The aim of this prospective, randomized trial was to compare endoscopic injection sclerotherapy with ligation with endoscopic injection sclerotherapy techniques in utility for patients with esophageal varices. Methodology: Twenty-four patients with esophageal varices who were to undergo either an elective treatment of bleeding esophageal varices or a prophylactic treatment of non-bleeding esophageal varices underwent endoscopic injection sclerotherapy with ligation (n=12) or without ligation (n=12). The patients were followed for a mean of 19.9+-8.1 months in the endoscopic injection sclerotherapy with ligation (EISL) group and 19.5+-5.4 months in the Endoscopic injection sclerotherapy (EIS) group. Results: The red color sign disappeared in 10 patients in the EISL group and 3 in the EIS group (P=0.004) after initial treatment. The length of time required for initial treatment was 16.3+-4.7 min for the EISL group and 27.2+-6.2 min for the EIS group (P=0.0003). For treatment-related complications, no significant difference was noted between the 2 groups and no serious complication were noted in the 2 groups. The total quantity of ethanolamine oleate used to attain the endpoint was 17.3+-7.9mL for the EISL group and 25.2+-9.7mL for the EIS group (P<0.05). The cumulative non-relapse rate for 2 years following attainment of the endpoint (F1, RC(-)) was 81.5% for the EISL group and 47.5% for the EIS group, producing no significant difference between the 2 groups. The cumulative non-bleeding and survival rates were 100% in the 2 groups. Conclusions: Endoscopic injection sclerotherapy with ligation is more useful for esophageal varices than endoscopic injection sclerotherapy alone.